DRUGDOCS | Vyvanse®

Drug updated on 12/11/2024

Dosage Form	Capsule (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg); Chewable tablet (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg)
Drug Class	Central nervous system stimulants
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older

Indicated for the treatment of moderate to severe binge eating disorder (BED) in adults.

This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
Reduction of Binge-Eating Disorder (BED) Symptoms and Body Weight in Clinical Populations: Lisdexamfetamine (LDX) has demonstrated effectiveness in reducing both BED symptoms and body weight in patients diagnosed with BED, as supported by clinical studies.
Reduction of Food Intake in Preclinical Models: Preclinical studies on rodent models indicate that LDX reduces overall food intake, though it does not consistently decrease the intake of specifically palatable foods.
Absence of Comparative Drug Data and Population-Specific Outcomes: No other pharmacotherapies are mentioned for direct comparison with LDX in treating BED, nor are there details on effectiveness across different population types or subgroups.
There is no safety information available in the reviewed studies.

Document Title	Year	Source
Vyvanse (lisdexamfetamine dimesylate) Prescribing Information.	2023	Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA

Document Title	Year	Source
Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies	2023	Biomolecules
Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder	2021	European Neuropsychopharmacology : the Journal of the European College of

Document Title	Year	Source
Clinical practice guideline for the pharmacological and psychological treatment of adult patients with attention deficit hyperactivity disorder and a comorbid diagnosis of substance use disorder.	2023	Adicciones
The American Psychiatric Association practice guideline for the treatment of patients with eating disorders.	2022	American Psychiatric Association
Treatment strategies for ADHD: An evidence-based guide to select optimal treatment	2019	Molecular Psychiatry
Attention deficit hyperactivity disorder: Diagnosis and management. NICE guideline [NG87]	2019	NICE
Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: A critical look.	2019	BMJ Evidence-based Medicine